Drug Trial Radar · NCT01628549
Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris
Last checked: Nov 20, 2026Latest source record: Feb 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
285
Actual
Start
Jun 30, 2012
Primary completion
Nov 16, 2012
Study completion Jan 31, 2013
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- Collaborators
- Allergan
- First posted
- Jun 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
50 mg P005672-HClDrug
P005672-HCl administered as an oral capsule(s) once daily
PlaceboDrug
Dose-matched Placebo capsule administered as an oral capsule(s) once daily
100 mg P005672-HClDrug
P005672-HCl administered as an oral capsule(s) once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final VisitTime frame: Baseline (Week 0) to Final Visit (Up to Week 12)
- The Dichotomized IGA (Investigator Global Assessment) Score at Final VisitTime frame: Final Visit (Up to Week 12)
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Warner Chilcott Investigational Site
Mobile, Alabama
Warner Chilcott Investigational Site
Tucson, Arizona
Warner Chilcott Investigational Site
Hot Springs, Arkansas
Warner Chilcott Investigational Site
Los Angeles, California
Warner Chilcott Investigational Site
San Diego, California
Warner Chilcott Investigational Site
Santa Monica, California
Warner Chilcott Investigational Site
Clearwater, Florida
Warner Chilcott Investigational Site
Coral Gables, Florida
Warner Chilcott Investigational Site
Gainesville, Florida
Warner Chilcott Investigational Site
Miami, Florida
Warner Chilcott Investigational Site
Miramar, Florida
Warner Chilcott Investigational Site
Pinellas Park, Florida
Warner Chilcott Investigational Site
Arlington Heights, Illinois
Warner Chilcott Investigational Site
Chicago, Illinois
Warner Chilcott Investigational Site
Granger, Indiana
Warner Chilcott Investigational Site
Indianapolis, Indiana
Warner Chilcott Investigational Site
Louisville, Kentucky
Warner Chilcott Investigational Site
Boston, Massachusetts
Warner Chilcott Investigational Site
Fridley, Minnesota
Warner Chilcott Investigational Site
St Louis, Missouri
Warner Chilcott Investigational Site
Berlin, New Jersey
Warner Chilcott Investigational Site
Albuquerque, New Mexico
Warner Chilcott Investigational Site
Rochester, New York
Warner Chilcott Investigational Site
Rochester, New York
Warner Chilcott Investigational Site
Charlotte, North Carolina
Warner Chilcott Investigational Site
Salisbury, North Carolina
Warner Chilcott Investigational Site
Wilmington, North Carolina
Warner Chilcott Investigational Site
Cincinnati, Ohio
Warner Chilcott Investigational Site
Portland, Oregon
Warner Chilcott Investigational Site
Philadelphia, Pennsylvania
Warner Chilcott Investigational Site
Greer, South Carolina
Warner Chilcott Investigational Site
Arlington, Texas
Warner Chilcott Investigational Site
Austin, Texas
Warner Chilcott Investigational Site
Houston, Texas
Warner Chilcott Investigational Site
Plano, Texas
Warner Chilcott Investigational Site
San Antonio, Texas
Warner Chilcott Investigational Site
Sandy City, Utah
Warner Chilcott Investigational Site
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.